The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 07, 2024
Filed:
Jun. 25, 2021
Applicant:
Santen Pharmaceutical Co., Ltd., Osaka, JP;
Inventors:
Assignee:
SANTEN PHARMACEUTICAL CO., LTD., Osaka, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/444 (2006.01); A61K 31/225 (2006.01); A61K 31/4178 (2006.01); A61K 31/498 (2006.01); A61K 31/5377 (2006.01); A61K 31/542 (2006.01); A61K 31/551 (2006.01); A61K 31/5575 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/444 (2013.01); A61K 31/225 (2013.01); A61K 31/4178 (2013.01); A61K 31/498 (2013.01); A61K 31/5377 (2013.01); A61K 31/542 (2013.01); A61K 31/551 (2013.01); A61K 31/5575 (2013.01); A61K 45/06 (2013.01); C07D 401/14 (2013.01);
Abstract
A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.